This phase II LUNG-MAP treatment trial studies how well sapanisertib and docetaxel work for the treatment for squamous cell lung cancer that is stage IV or has come back (recurrent). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sapanisertib and docetaxel may work better in treating patients with squamous cell lung cancer compared to standard chemotherapy.

NCT04267913

Conditions

1. Lung Squamous Cell Carcinoma
2. Recurrent Lung Carcinoma
3. Stage IV Lung Cancer AJCC v8
4. Stage IVA Lung Cancer AJCC v8
5. Stage IVB Lung Cancer AJCC v8

Interventions

1. Drug: Dexamethasone
2. Drug: Docetaxel
3. Biological: Ramucirumab
4. Drug: Sapanisertib

MeSH:Carcinoma Lung Neoplasms

HPO:Carcinoma Neoplasm of the lung

Hazard ratios for these outcomes will be estimated using a Cox Proportional Hazards regression model adjusting for the stratification factors.. Inclusion Criteria: - Patients must be assigned to S1900D. --- S1900D ---

Assignment to S1900D is determined by the S1400 or LUNGMAP protocol genomic profiling using the FoundationOne assay. --- S1900D ---

Biomarker eligibility for S1900D is based on the identification of an NFE2L2 mutation or KEAP1 alteration - Patients must have a histologically or cytologically confirmed stage IV or recurrent pure squamous cell lung cancer - Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI). --- S1900D ---

However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures Inclusion Criteria: - Patients must be assigned to S1900D. --- S1900D ---